Skip to main
  1. Stocks
  2. Solid Biosciences
  3. Forecast
SLDB

Solid Biosciences (SLDB) Stock Forecast & Price Target

Solid Biosciences (SLDB) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 55%
Buy 45%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Solid Biosciences is attractive because its SGT-003 DMD program combines a differentiated capsid, the unique R16/R17 nNOS feature, and a steroid-only prophylaxis regimen that has shown no drug-induced liver injury in 53 dosed patients, alongside consistent biomarker evidence across expression, CK, troponin, and LVEF. The company is also better positioned than before to navigate regulation, with FDA leadership viewed as more constructive and a randomized confirmatory trial already underway, which could support a favorable accelerated-approval discussion in late 4Q26. Beyond DMD, SGT-212, SGT-501, and SGT-601 add optionality, while the stock’s enterprise value of about $700m appears to underwrite limited credit for a platform that could address a large, still-untreated DMD population and broader cardiac and neuromuscular diseases.

Bears say

Solid Biosciences is viewed negatively because its core gene-therapy platform remains exposed to unresolved clinical, regulatory, and safety risks, including the possibility of immune-mediated toxicity, clinical holds, and failures to prove sustained efficacy. The company’s dependence on a small set of programs means a setback in DMD, FA, or CPVT could impair platform value materially, while competition and pricing pressure could compress any eventual commercial opportunity. Financially, the balance sheet appears limited for a development-stage biotech, with ~$236 million in cash, cash equivalents, investments, and available-for-sale securities as of September 30, 2025, leaving a meaningful likelihood that additional financing or partnerships will be needed.

Solid Biosciences (SLDB) has been analyzed by 11 analysts, with a consensus rating of Buy. 55% of analysts recommend a Strong Buy, 45% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Solid Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Solid Biosciences (SLDB) Analyst Forecast & Price Prediction

Get the latest Solid Biosciences (SLDB) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Solid Biosciences (SLDB)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Solid Biosciences (SLDB) Forecast

Analysts have given Solid Biosciences (SLDB) a Buy based on their latest research and market trends.

According to 11 analysts, Solid Biosciences (SLDB) has a Buy consensus rating as of Nov 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.55, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.55, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Solid Biosciences (SLDB)


Solid Biosciences (SLDB) Analyst Forecast & Price Prediction

Get the latest Solid Biosciences (SLDB) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Solid Biosciences (SLDB)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover SLDB stock data and trends